Natpar (Parathyroid Hormone)

Natpar is a parathyroid hormone analog used to manage disorders of calcium metabolism, particularly hypoparathyroidism.

• Chronic hypoparathyroidism: restores and maintains normal serum calcium concentrations in patients with long‑term deficiency of endogenous parathyroid hormone.
• Post‑surgical hypoparathyroidism: corrects acute hypocalcemia following thyroid or parathyroid surgery when natural hormone production is insufficient.
• Severe hypocalcemia unresponsive to conventional therapy: provides an alternative means to raise calcium levels when oral calcium and vitamin D supplementation fail.

• Parathyroid hormone binds to the PTH1 receptor on osteoblasts, renal tubular cells and the intestine, activating adenylate cyclase and phospholipase C pathways. This signaling stimulates bone resorption, enhances renal calcium reabsorption, and promotes 1‑α‑hydroxylase activity, increasing conversion of vitamin D to its active form, thereby raising serum calcium concentrations. The combined effect rapidly corrects hypocalcemia while also supporting long‑term calcium homeostasis.

Parathyroid hormone therapy may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild gastrointestinal discomfort occurring shortly after injection.
• Injection site reactions: redness, swelling or pain at the subcutaneous administration site.
• Headache: transient cranial discomfort reported by some patients.
• Hypercalcemia (mild): slight elevation of serum calcium that is usually manageable with dose adjustment.

Serious or Rare Side Effects

• Severe hypercalcemia: marked increase in calcium that can cause cardiac arrhythmias or renal impairment.
• Ectopic calcification: deposition of calcium in soft tissues, potentially affecting kidneys or vasculature.
• Anaphylactic reaction: rare systemic hypersensitivity requiring immediate medical intervention.
• Osteosarcoma (theoretical risk): observed in animal studies, considered a potential but unproven risk in humans.

When using Natpar, clinicians should observe specific safety measures to minimize risks and ensure therapeutic effectiveness.

• Monitor serum calcium: check calcium levels regularly and adjust dose to maintain target range.
• Adjust dose in renal impairment: reduce dosage or increase monitoring in patients with reduced kidney function.
• Caution in hypercalcemia: avoid use or lower dose if baseline calcium is elevated.
• Pregnancy and lactation: safety has not been established; use only if potential benefit justifies risk.
• Concomitant calcium or vitamin D therapy: evaluate need to prevent excessive calcium rise.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Parathyroid hormone can interact with other agents that influence calcium balance or bone metabolism.

Major Interactions (Avoid)

• High‑dose calcium supplements: may cause dangerous hypercalcemia when combined with Natpar.
• High‑dose vitamin D analogs (calcitriol, alfacalcidol): synergistic increase in calcium absorption.
• Thiazide diuretics: reduce renal calcium excretion, raising risk of hypercalcemia.

Moderate Interactions (Monitor Closely)

• Bisphosphonates: may blunt the bone‑resorbing effect of Natpar, affecting calcium response.
• Calcitonin therapy: opposing actions on calcium homeostasis may require dose adjustments.
• Loop diuretics: increase calcium excretion, potentially necessitating higher Natpar dose.